18_CD 17c_JJ GROUP_NNP PROFIT_NNPS AND_CC LOSS_NNPS ACCOUNT_NN For_IN the_DT year_NN ended_VBD 31_CD December_NNP Cost_NN of_IN sales_NNS -_: restatement_NN 2001_CD 2000_CD The_DT Group_NNP has_VBZ begun_VBN to_TO classify_VB the_DT 2002_CD restated_VBN restated_VBN Notes_NNP 000 000 000_CD costs_NNS directly_RB attributable_JJ to_TO funded_JJ Turnover_NN 2_CD 79,716_CD 8,914_CD 6,264_CD research_NN and_CC vaccine_NN manufacture_NN Cost_NN of_IN sales_NNS 49,249_CD 5,063_CD 517_CD programs_NNS as_IN cost_NN of_IN sales_NNS ,_, rather_RB Gross_NNP profit_NN 30,467_CD 3,851_CD 5,747_CD than_IN research_NN and_CC development_NN Research_NN and_CC development_NN costs_NNS 16,299_CD 12,594_CD 12,195_CD expenditure_NN ._.
This_DT is_VBZ because_IN the_DT Administrative_JJ costs_NNS including_VBG amortisation_NN of_IN goodwill_NN 3_CD 4,257_CD 3,499_CD 2,949_CD Directors_NNS believe_VBP this_DT classification_NN Group_NNP operating_NN profit_NN loss_NN 4_CD 9,911_CD 12,242_CD 9,397_CD more_JJR appropriately_RB reflects_VBZ the_DT Share_NN of_IN loss_NN of_IN joint_JJ venture_NN 14_CD d_SYM 171_CD 410_CD 2,138_CD nature_NN of_IN the_DT arrangements_NNS into_IN Total_JJ operating_NN profit_NN loss_NN before_IN exceptional_JJ items_NNS Group_NNP and_CC joint_JJ venture_NN 9,740_CD 12,652_CD 11,535_CD which_WDT the_DT Group_NNP has_VBZ entered_VBN ._.
In_IN the_DT Exceptional_JJ items_NNS :_: three_CD financial_JJ years_NNS shown_VBN ,_, cost_NN of_IN Profit_NN on_IN disposal_NN of_IN fixed_JJ asset_NN investment_NN -_: -_: 221_CD sales_NNS represent_VBP only_RB those_DT costs_NNS Profit_NN on_IN sale_NN of_IN discontinued_VBN operations_NNS -_: -_: 414_CD incurred_VBN on_IN the_DT two_CD CDC_NNP smallpox_NN Amounts_NNS written_VBN off_RP fixed_VBN asset_NN investment_NN 5_CD 85 423 670_CD vaccine_NN contracts_NNS ._.
The_DT restatement_NN Profit_NN loss_NN on_IN ordinary_JJ activities_NNS before_IN finance_NN charges_NNS 9,655_CD 13,075_CD 11,570_CD of_IN 2001_CD and_CC 2000_CD costs_NNS from_IN R&D_NNP Interest_NNP receivable_JJ 685 857 983_CD costs_NNS to_TO cost_NN of_IN sales_NNS amounted_VBD to_TO Interest_NNP payable_JJ and_CC similar_JJ charges_NNS 6_CD 1,211_CD 214_CD 216_CD 5.1_CD m_NN and_CC 0.1_CD m_NN respectively_RB ._.
There_EX Exchange_NNP gain_NN loss_NN on_IN foreign_JJ currency_NN borrowings_NNS 18 449 126 271_CD is_VBZ no_DT impact_NN on_IN net_JJ profit_NN ._.
Profit_NN loss_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN 7_CD 9,578_CD 12,558_CD 11,074_CD Taxation_NNP 10_CD 3_CD 131_CD -_: Turnover_NN and_CC profit_NN Profit_NN loss_NN on_IN ordinary_JJ activities_NNS after_IN taxation_NN being_VBG retained_VBN profit_NN loss_NN for_IN the_DT financial_JJ year_NN 9,575_CD 12,427_CD 11,074_CD The_DT increase_NN in_IN turnover_NN and_CC the_DT Earnings_NNS loss_NN per_IN ordinary_JJ share_NN basic_JJ 11_CD 10.0_CD p_NN 13.7_CD p_VBP 13.9_CD p_JJ Earnings_NNS loss_NN per_IN ordinary_JJ share_NN fully_RB diluted_VBN 11_CD 9.7_CD p_NN 13.7_CD p_VBP 13.9_CD p_JJ recording_NN of_IN a_DT maiden_JJ profit_NN in_IN 2002_CD has_VBZ principally_RB been_VBN driven_VBN by_IN the_DT A_NNP statement_NN of_IN movements_NNS on_IN reserves_NNS is_VBZ given_VBN in_IN note_NN 22_CD ._.
second_JJ smallpox_NN vaccine_NN contract_NN with_IN the_DT US_NNP Government_NNP agency_NN ,_, the_DT The_DT accompanying_JJ notes_NNS are_VBP an_DT integral_JJ part_NN of_IN this_DT Group_NNP profit_NN and_CC loss_NN account_NN ._.
Centers_NNPS for_IN Disease_NNP Control_NNP and_CC All_DT amounts_NNS in_IN 2002_CD arise_VB from_IN continuing_VBG operations_NNS see_VBP note_NN 4_CD ._.
Taxation_NNP The_NNP tax_NN charge_NN relating_VBG to_TO 2002_CD was_VBD negligible_JJ due_JJ to_TO the_DT availability_NN of_IN tax_NN losses_NNS within_IN the_DT Group_NNP ._.
We_PRP hope_VBP that_IN when_WRB the_DT remaining_VBG tax_NN 17d_CD GROUP_NNP STATEMENT_NNP OF_IN TOTAL_NNP RECOGNISED_NNP GAINS_NNPS AND_CC LOSSES_NNPS losses_NNS can_MD be_VB utilised_VBN ,_, this_DT will_MD have_VB For_IN the_DT year_NN ended_VBD 31_CD December_NNP the_DT effect_NN of_IN lowering_VBG the_DT effective_JJ tax_NN rate_NN ._.
2002 2001 2000 000_CD 000_CD 000_CD Profit_NN loss_NN for_IN the_DT year_NN 9,575_CD 12,427_CD 11,074_CD Gain_NNP loss_NN on_IN foreign_JJ currency_NN translation_NN 1,276_CD 314_CD 817_CD Total_JJ recognized_VBN gains_NNS and_CC losses_NNS for_IN the_DT year_NN 10,851_CD 12,741_CD 11,891_CD The_DT accompanying_JJ notes_NNS are_VBP an_DT integral_JJ part_NN of_IN this_DT Group_NNP statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS ._.
THE_DT INFORMATION_NN CONTAINED_VBD IN_IN THIS_NNP COLUMN_NNP HAS_VBZ NOT_RB BEEN_JJ AUDITED_NN ._.
